Trending News Today: Psoriasis Drug Effectively Treats Chronic Bowel Disease in Trial

Johnson & Johnson’s psoriasis drug Stelara effectively treated chronic bowel disease in a late-stage trial, Reuters reported. According to the article, both 6 mg/kg and 130 mg doses of Stelara showed clinical remission in significantly more patients with moderate-to-severe ulcerative colitis who had failed prior therapy compared with those on placebo after 8 weeks. Stelara is already approved for psoriasis, psoriatic arthritis, and Crohn disease, the article reported.
Staff reviewers with the FDA raised safety concerns over Trevena Inc’s opioid injection, oliceridine, to treat acute pain, Reuters reported. According to the article, the treatment aims to manage moderate-to-severe acute pain in adult patients for whom an intravenous opioid is warranted. However, in an overall assessment of the abuse-related data, FDA staff reviewers indicated that oliceridine has abuse potential, overdose potential, and the ability to cause physical dependence that is similar to other such treatments, the article reported.
A new survey found that 62% of Americans favor legalization of marijuana, The Hill reported. According to the article, the Pew Research Center survey was conducted among a sample population of 1754 adults and showed that support for marijuana legalization jumped just 1% from 2017 and has doubled from the 31% reported in 2000. The poll also found that support for medical marijuana reached 93%, the article reported. 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

A phase 4 head-to-head trial compared ixekizumab (Taltz) with guselkumab (Tremfya) in patients with moderate-to-severe plaque psoriasis.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.